Heidelberg, Germany, July 16, 2024 – Heidelberg Epignostix, a deeptech start-up committed to precision cancer diagnostics today announces the appointment of Helge Lubenow as CEO. She will be succeeding founder David Jones in the role who will continue to support Heidelberg Epignostix as Chief Scientific Officer. Helge Lubenow has almost 25 years of industry experience and held senior positions in the life sciences and diagnostics industry. She began her career at QIAGEN where she ultimately served as Head of the Diagnostics Business.
“We are very excited for Helge to support us in the next phase of our development” said David Jones, “as we are committed to creating a transformative portfolio of cancer diagnostic tools in brain tumors and beyond.” Felix Sahm, co-founder and Head of Molecular Neuropathology at the Heidelberg University Hospital adds: “There is a high unmet need in personalized patient management that calls for the rapid development of a clinically certified tool, to enable routine use and broad adoption for improved patient outcomes.”
“I feel very honored being able to join such a world-class team and am deeply impressed about the achievements that have been made already. I am committed to improving cancer care and quality of life outcomes for the benefit of patients and their families, community and ultimately society” said Helge Lubenow.
related posts
A substantial update to the sarcoma tumour classifier, extending precision methylation-based classification beyond tumours of the central nervous system.
Prof. Dr. Dr. med. Felix Sahm joins as Chief Medical Advisor, guiding clinical and medical strategy as the company expands its precision diagnostics portfolio.
A €4.3M seed round led by CARMA FUND I, with High-Tech Gründerfonds, LBBW Venture Capital and Start-up BW, to accelerate brain tumour classification.
